Quarterly Result21 Jul 2026, 05:00 pm
Anthem Biosciences Q1FY27 Revenue ₹4,182 Mn, PAT ₹1,199 Mn
AI Summary
Anthem Biosciences Ltd announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,182 Mn, with EBITDA at ₹1,755 Mn (39.6% margin) and Profit After Tax (PAT) at ₹1,199 Mn (27.1% margin). Revenue from the CRDMO business was ₹3,408 Mn, and Specialty Ingredients contributed ₹774 Mn. The company noted timing shifts in deliveries to key customers, expecting stronger momentum in the latter half of the year. Management highlighted year-on-year improvement in EBITDA and PAT margins due to cost efficiencies and productivity.
Key Highlights
- Consolidated Revenue from Operations stood at ₹4,182 Mn for Q1FY27.
- EBITDA reported at ₹1,755 Mn with healthy margins of 39.6%.
- PAT for the quarter was ₹1,199 Mn, achieving a margin of 27.1%.
- CRDMO business contributed ₹3,408 Mn to revenue.
- Company expects stronger performance in H2 FY27 due to delivery shifts.
Price Impact
More from ANTHEM